奥希替尼联合阿司匹林对晚期肺腺癌EGFR突变患者生存期的影响

Effect of osimertinib combined with aspirin on survival period in advanced lung adenocarcinoma patients with EGFR mutation

目的 探讨奥希替尼联合阿司匹林对晚期肺腺癌表皮生长因子受体(EGFR)突变患者生存期的影响。方法 选取2020年8月至2021年10月首诊于重庆市巴南区第二人民医院的60例晚期非小细胞肺癌(NSCLC)中肺腺癌EGFR突变患者为研究对象,采用随机数字表法分为观察组和对照组,每组30例。观察组采用奥希替尼联合阿司匹林,对照组单用奥希替尼。比较两组用药后的总有效率(ORR)、疾病控制率(DCR)、无进展生存(PFS)时间、总生存(OS)时间及不良反应发生情况。结果 用药3、6、12个月,观察组ORR、DCR均高于对照组,但差异无统计学意义(P>0.05)。与对照组比较,观察组PFS[14.9(11.8,17.2)个月vs.10.5(8.9,12.5)个月]、OS[24.1(19.5,27.4)个月vs.18.1(16.1,21.1)个月]时间更长,差异有统计学意义(P<0.05)。此外,观察组男性、女性、脑转移、EGFR19及21外显子突变患者PFS、OS时间均长于对照组,差异有统计学意义(P<0.05)。两组总体及≥Ⅲ度不良反应发生率比较,差异无统计学意义(P>0.05)。结论 奥希替尼联合阿司匹林能延长晚期肺腺癌EGFR突变患者的PFS、OS时间,且不会增加不良反应风险。

Objective To investigate the effect of osimertinib combined with aspirin on the survival period of the advanced lung adenocarcinoma patients with epidermal growth factor receptor(EGFR) mutation.Methods Sixty lung adenocarcinoma patients with EGFR mutation in advanced non-small cell lung cancer(NSCLC) first diagnosed in Banan District Second People's Hospital of from August 2020 to October 2021 were selected as the study subjects and divided into the observation group and control group by the random number table method,30 cases in each group.The observation group adopted osimertinib combined with aspirin,and the control used osimertinib merely.The overall response rate(ORR),disease control rate(DCR),progression-free survival(PFS),overall survival(OS) and the adverse reactions occurrence were compared between the two groups.Results ORR and DCR after 3,6,12 months medication in the observation group were higher than those in the control group,but the differences were not statistically significant(P>0.05).Compared with the control group,PFS and OS in the observation group were longer,and the differences were statistically significant [14.9(11.8,17.2)m vs.10.5(8.9,12.5)m;24.1(19.5,27.4)m vs.18.1(16.1,21.1)m,P<0.05].In addition,PFS and OS in male and female patients with brain metastasis,EGER19 and 21 exon mutation in the observation group were longer than those in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in overall and ≥Ⅲ degree adverse reactions between the two groups(P>0.05).Conclusion Osimertinib combined with aspirin could prolong PFS and OS of the advanced lung adenocarcinoma patients with EGFR mutation without increasing the risk of adverse reactions.